{"id":"inf1-0-ibu","safety":{"commonSideEffects":[{"rate":null,"effect":"Flu-like symptoms (fever, chills, fatigue)"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL508802","moleculeType":"Small molecule","molecularWeight":"985.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon alfa-1b is a recombinant interferon that activates natural killer cells and macrophages to enhance antiviral immunity and has immunomodulatory properties. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce inflammation and pain. The combination aims to leverage both immune activation and symptomatic relief.","oneSentence":"INF1.0 + IBU is a combination of interferon alfa-1b and ibuprofen that combines antiviral/immunomodulatory effects with anti-inflammatory and analgesic activity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:33:16.122Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Viral infections (specific indication not clearly documented in available sources)"}]},"trialDetails":[{"nctId":"NCT02985177","phase":"PHASE4","title":"A RCT of a Combination of Analgesics for Pain Management in Children With a Suspected Fracture","status":"WITHDRAWN","sponsor":"St. Justine's Hospital","startDate":"2020-01","conditions":"Emergency Service, Hospital, Child/Adolescent Problem, Acute Pain","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1517,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"INF1.0 + IBU","genericName":"INF1.0 + IBU","companyName":"St. Justine's Hospital","companyId":"st-justine-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"INF1.0 is a small molecule that, when combined with ibuprofen, is being studied in a clinical trial for pain management in children with a suspected fracture. This combination, known as INF1.0 + IBU, is being investigated in a randomized controlled trial at St. Justine's Hospital.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}